4//SEC Filing
Horn Margaret A 4
Accession 0001610717-26-000013
CIK 0001628171other
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 4:20 PM ET
Size
16.0 KB
Accession
0001610717-26-000013
Insider Transaction Report
Form 4
Horn Margaret A
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-07$42.45/sh+51,406$2,182,185→ 192,459 total - Exercise/Conversion
Common Stock
2026-01-07$29.80/sh+23,594$703,101→ 216,053 total - Sale
Common Stock
2026-01-07$100.02/sh−53,096$5,310,471→ 162,957 total - Sale
Common Stock
2026-01-07$101.79/sh−20,204$2,056,622→ 142,753 total - Sale
Common Stock
2026-01-07$102.90/sh−1,700$174,930→ 141,053 total - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−51,406→ 1,094 totalExercise: $42.45From: 2023-08-09Exp: 2031-03-03→ Common Stock (51,406 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−23,594→ 119,906 totalExercise: $29.80Exp: 2034-02-28→ Common Stock (23,594 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025.
- [F2]Includes 61,226 restricted stock units.
- [F3]This transaction was executed in multiple trades in prices ranging from $100.00 to $100.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]This transaction was executed in multiple trades in prices ranging from $101.07 to $101.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001294192
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 4:20 PM ET
- Size
- 16.0 KB